Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProSci-246 is an investigational live biotherapeutic product (probiotic formulation) currently being evaluated for its potential therapeutic benefits in patients with type 2 diabetes mellitus and obesity. Developed by researchers at Weihai Municipal Hospital, the agent is designed to modulate the intestinal microbiome, thereby influencing metabolic pathways and the gut-brain axis. In clinical trials, ProSci-246 is administered orally in combination with metformin to investigate its effects on glycemic control, body composition, systemic inflammation, and neuropsychological outcomes including cognition, mood, and sleep quality. The treatment aims to restore microbial homeostasis and promote the production of beneficial metabolites that enhance insulin sensitivity and metabolic health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProSci-246.